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In general, strategies for the treat-
ment of cancer in pregnancy should 
not differ significantly from the treat-
ment regimens in non-pregnant wom-
en. However, this is difficult due to 
either the effects of anticancer drugs 
on the developing foetus or the possi-
bility of long-term complications after 
the exposure to drugs and radiation.
The decision about the introduction 
and continuation of treatment in the 
event of pregnancy should be pre-
ceded by a detailed analysis of the 
potential benefits and risks. There 
are no data to suggest that pregnan-
cy termination alters the biological 
behaviour of the tumour or patient 
prognosis in the presence of appropri-
ate antineoplastic therapy. All patients 
should be given appropriate advice 
and informed that there are insuffi-
cient scientific data to determine any 
generally accepted consensus. It is 
very important to always respect the 
will of the patient, and the moral judg-
ment of the physician should have no 
impact on the decisions taken by the 
woman. If the woman decides to un-
dergo active treatment and maintain 
her pregnancy, it is necessary to carry 
out consultations with experts in the 
field appropriate to the type of cancer.
This paper presents a basic review of 
the literature on the targeted thera-
pies currently used in selected cancers 
diagnosed during pregnancy: breast 
cancer, cervical cancer, Hodgkin’s dis-
ease, melanoma, thyroid cancer, ovar-
ian cancer, and colorectal cancer.
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Introduction
Malignancies in pregnant women account for 0.05–0.1% of all cancers. 
They are associated with 0.02–0.1% of all pregnancies; one in 1000–1500 
pregnancies is complicated by the presence of cancer in the mother [1, 2]. 
There is some controversy about the effects of pregnancy on the progression 
and prognosis of cancer. Current knowledge is based on the results of phase 
II studies, retrospective analyses, and systematic reviews of the literature. 
For this reason, clinically relevant decisions are often made without knowl-
edge of reliable scientific data.
In general, strategies for the treatment of cancer in pregnancy should not 
differ significantly from the treatment regimens in non-pregnant women. 
However, this is difficult due to either the effects of anticancer drugs on 
the developing foetus or the possibility of long-term complications after the 
exposure to drugs and radiation.
Following a diagnosis of cancer in pregnancy, the decision about how to 
proceed should be made jointly by a multidisciplinary team consisting of 
a surgeon, a clinical oncologist, a specialist in radiation therapy in oncologi-
cal gynaecology, an obstetrician, and a psychologist, with active involvement 
and support from the family of the pregnant patient. This paper presents 
a basic review of the literature on the targeted therapies currently used in 
selected cancers diagnosed during pregnancy: breast cancer, cervical cancer, 
Hodgkin’s disease, melanoma, and thyroid cancer.
Therapeutic options in pregnant patients with cancer
Surgery
Surgery is the mainstay of treatment of solid tumours, and pregnancy is 
not a contraindication to a surgery. Thanks to the use of modern surgical 
techniques and anaesthesia, maternal mortality is negligible. Operation in 
the first trimester does not appear to increase major birth defects, but the 
risk of miscarriage increases. Therefore, when possible, surgery should be 
deferred until the second trimester, when the risk to the foetus is lowest.
Surgical treatment of non-neoplastic conditions in pregnant women in-
cludes cases of cholecystitis, appendicitis, and ovarian cysts. Anaesthesia 
during pregnancy is considered to be safe [3] and most anaesthetics are 
safe for the foetus [4]. Negative effects for the foetus are more correlated 
with maternal hypoxia, hypotension, hypothermia, or abnormal glucose me-
tabolism than with anaesthesia. The risk of pregnancy loss and congenital 
defects does not increase because of surgery. Preterm births usually occur 
in cases of abdominal surgeries and peritonitis [5, 6]. Since pain can also 
induce premature labour, it is important to administer appropriate postoper-
ative analgesia. Moreover, prophylaxis of thrombosis should also be imple-
mented [7]. A surgery in the first trimester slightly increases the risk of foetal 
loss due to general anaesthesia [8]. Laparoscopic surgery can be carried out 
during pregnancy by an experienced physician [5, 6].
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Chemotherapy
Most of the damage to the foetus has been reported 
during embryogenesis and organogenesis (up to the 60th 
gestation day), which justifies dispensing with any che-
motherapy (CTH) in the first trimester of pregnancy. Af-
ter the administration of cytotoxic chemotherapy during 
pregnancy, especially during the first trimester, the occur-
rence of birth defects is about 20%, 40% of which regard 
low birth weight, and about 33% of which regard pancy-
topenia [9]. The most adverse antimetabolites are ami-
nopterin, methotrexate, and cytosine arabinoside, and in 
the group of alkylating agents – chlorambucil, mechlore-
thamine, and cyclophosphamide. In the literature there is 
no information on the threat posed to the foetus by plant 
alkaloids and anthracyclines because they are composed 
of large molecules, which probably have more difficulty in 
passing through the placenta. Platinum derivatives cause 
some delay in the development of the foetus and may 
cause hearing deficiency. Etoposide can cause pancytope-
nia in foetuses and newborns, and a higher risk of second-
ary leukaemia. A number of reports on the use of toxoids 
(docetaxel and paclitaxel) in pregnancy indicate no harm 
to the foetus in the second and third trimester of pregnan-
cy in pregnant women treated for breast cancer and ovar-
ian cancer. If the use of chemotherapeutics during preg-
nancy is necessary, the least harmful platinum preparation 
is cisplatin (carboplatin is more toxic to the bones), while 
among anthracyclines, doxorubicin is recommended. The 
use of epirubicin and liposomal forms of anthracyclines is 
more dangerous because of the higher degree to which 
these drugs overcome the barrier of the placenta [10].
Most cytotoxic drugs have a relatively low molecular 
weight and can cross the placenta. Because of its tera-
togenic and mutagenic effect, chemotherapy is contrain-
dicated during the first trimester of pregnancy. However, 
in some cases, chemotherapy is used after the period of 
organogenesis. Breast-feeding by pregnant women under-
going CTH is contraindicated because the drugs are ex-
creted with breast milk [10]. Tamoxifen and aromatase in-
hibitors should be deferred until after the delivery, due to 
their teratogenic effect observed in animals and humans 
[11]. Table 1 shows the main risks to the foetus of chemo-
therapeutic agents.
Radiation therapy
The adverse effects of radiation were first described 
at the beginning of the previous century. Cases of birth 
defects have been reported in children of mothers who 
received a dose of radiation to the pelvic area during 
pregnancy. Such children demonstrated microcephaly, 
mental retardation, stunted growth, microphthalmus, ret-
inal degeneration, cataracts, and defective dentition [12]. 
In principle, radiation therapy should be avoided during 
pregnancy, if possible. The neck and mediastinum can be 
considered as an area for irradiation, provided that the re-
gion of the pelvis is excluded.
The biological effect of irradiation depends on the 
stage of pregnancy, the radiation dose, and the amount 
of the treatment area covering the foetus. The Interna-
tional Commission on Radiological Protection (ICRP) con-
siders doses lower than 1 mGy to have negligible effect 
on the foetus and doses of a few mGy are permitted and 
are not associated with an increased risk of birth defects 
[13]. Frequent side effects associated with the use of ra-
diation therapy (RT) during pregnancy are fatal damage, 
miscarriage, organ damage, stunted physical and mental 
health of the foetus, and carcinogenesis [14]. Exposure of 
the foetus to radiation doses exceeding 5–10 cGy should 
be avoided. Doses below this limit are associated with a 
very low risk of mutation, and developmental disorders do 
not occur at a frequency higher than that observed in the 
general population (3–5%). Exposure to anticancer agents 
should be avoided in the first trimester (organogenesis), 
but can be justified, at the cost of a slight increase in the 
risk for mother and foetus, in the second and third trimes-
ters of pregnancy [15, 16]. Table 2 shows the summary of 
potential effects on the developing embryo/foetus.
Treatment of tumours occurring during 
pregnancy
Breast cancer
Pregnancy-associated breast cancer (PABC) is defined 
as breast cancer occurring at any time during pregnancy, 
lactation, or within one year after the delivery. It occurs 
at a frequency of 1/3000–1/10,000 pregnancies, and about 
3% of all breast cancers coexist with pregnancy [17]. Physi-
ological changes in the mammary gland during pregnancy 
contribute to the delay in the diagnosis of breast cancer in 
pregnant women, amounting to an average of 5–7 months. 
The probability of detection of a metastatic tumour during 
pregnancy is 2.5 times higher than in the general popu-
lation, and the presence of metastases in regional lymph 
nodes is revealed in as many as 60% of cases [14, 17]. 
During pregnancy, usually unfavourable, poorly differenti-
ated forms of breast tumour are diagnosed, and most of 
them (approximately 80%) are characterised by the ab-
sence of expression of steroid receptors. Compared with 
Table 2. Summary of potential effects on the developing embryo/




Preimplantation lethal effects, data from rodents indicate 
1.5% loss with 0.1 Gy, 50% loss with 1 Gy
Postimplantation
weeks 1 to 8 
mental retardation, multiorgan 
malformation, growth retardation, 
microcephaly
weeks 8 to 15 mental retardation, microcephaly, possible 
skeletal and genital abnormalities, growth, 
retardation
weeks 15 to 25 major malformations unlikely, mild 
microcephaly, mental retardation, growth 
retardation
weeks > 30 unlikely to produce structural 
abnormalities, growth retardation still 
possible, major risks are increased cancer 
risk and potential effect on fertility
356 contemporary oncology
the cases occurring independently of pregnancy, tumours 
occurring during pregnancy often overexpress HER2 [18].
The available data indicate that surgery is safe through-
out pregnancy. Surgery is the primary treatment for early 
breast cancer. Modified radical mastectomy is the stan-
dard treatment in the first trimester of pregnancy. How-
ever, as a result of the required delay with the adjuvant 
radiation therapy, due to the risk to the foetus, a modified 
mastectomy is often performed. Following breast-conserv-
ing surgery, a complementary RT is administered after 3–6 
weeks. In case a systemic treatment is needed, RT begins 
3–6 weeks after CHTH. Therefore, a sparing surgery (with 
dissection) is preferably carried out in the second and third 
trimester of pregnancy [19, 20]. In these cases, radiation 
therapy is performed after birth. The lowest risk of miscar-
riage occurs in women treated surgically after 12 weeks of 
pregnancy [11, 21].
There are currently no adequate data on the safety of 
sentinel lymph node biopsy (SLNB) in pregnancy. In a pro-
spective study [22, 23] involving 12 pregnant patients with 
breast cancer who underwent the removal of lymph nodes 
with a radioactive marker, 11 children were born healthy 
and one was diagnosed with a hole in the septum of the 
heart. There is also the risk of an anaphylactic reaction in 
the mother in connection with the SLNB procedure [24]. 
The technique used to perform sentinel lymph node map-
ping was also evaluated in multiple studies, and the ac-
curacy rate increases when radiocolloid and blue dye are 
used in combination [25].
To summarise, SLNB can be performed in selected 
cases and only at oncology centres employing staff with 
appropriate experience [25]. Radiation therapy in the first 
trimester of pregnancy can cause developmental defects, 
microcephaly, mental retardation, growth retardation, 
haematological disorders, and can induce childhood can-
cer [26, 27].
An alternative to external beam radiotherapy appears 
to be an electron beam intraoperative radiotherapy (EL-
IOT) after a surgical, breast-conserving treatment. During 
the first and second trimester of pregnancy, ELIOT may 
be considered as part of the breast-conserving approach. 
After 30 weeks of pregnancy, when the foetus is much 
closer to the breast than at earlier stages, ELIOT is less 
secure [28].
Chemotherapy should be indicated for use in patients 
with unfavourable prognosis and should be completed in 
the second and third trimesters of pregnancy (e.g. 4–6 cy-
cles of AC or FAC regimens: doxorubicin and cyclophospha-
mide or doxorubicin, cyclophosphamide, and fluorouracil). 
The risk for the foetus related with FAC chemotherapy as 
adjuvant therapy is small [29, 30]. Hormone therapy is not 
used in pregnant patients because of the risk of its inter-
ference with the hormonal status associated with preg-
nancy, and additionally because of the high teratogenic 
potential of tamoxifen [31].
In women with locally advanced or metastatic breast 
cancer with overexpression of HER2, after failure of at 
least one chemotherapy, lapatinib (a small-molecule tyro-
sine kinase inhibitor of EGFR) can be used. To date, one 
case of pregnancy during treatment with lapatinib, used 
up to 14 weeks of gestation, has been described. During 
the 18-month follow-up period after birth, no defects in 
the child were revealed [30].
According to ESMO (European Society for Medical On-
cology) and the NCCN (National Comprehensive Cancer 
Network) Clinical Practice Guidelines in Oncology, the use 
of trastuzumab is contraindicated in pregnancy. In the lit-
erature on the use of trastuzumab in pregnant women, 
few cases have been described. Treatment with trastu-
zumab is associated with oligohydramnios (sometimes 
severe), lung aplasia, dysplastic kidney, and death shortly 
after birth [31–33]. Although the termination of pregnancy 
facilitates the therapy, it does not improve the prognosis 
[9, 16, 21, 26]. No data on breast reconstructive surgery in 
pregnancy are available.
Cervical cancer
Cervical cancer is the most frequent gynaecological tu-
mour diagnosed in pregnant women. As many as 1% of 
women diagnosed with cervical cancer are pregnant. The 
role of pregnancy in the carcinogenesis of cervical can-
Table 1. The main risks to the foetus of chemotherapeutic agents
Examples of chemotherapeutic agents The main risks to the foetus
Plant alkaloids:
vincristine, vinblastine, vinorelbine
Preterm delivery, intrauterine growth restriction (IUGR) [67]. Defect 
in the atrial septum [68].
Anthracycline antibiotics:
doxorubicin, daunorubicin, adriamycin, idarubicin, epirubicin, 
dactinomycine, bleomycin, mitoxantrone
Mid-trimester miscarriage, transient neonatal neutropenia, and 
sepsis, IUGR [69]. Transient myelosuppression [70].
Alkylating agents:
cyclophosphamide, busulfan, ifosphamide, chlorambucil, 
carmustine, dacarbazine
Absent toes, eye abnormalities, low-set ears, and cleft palate [71]. 
Oesophageal atresia, abnormal inferior vena cava [72]. Pyloric 
stenosis, renal agenesis, and liver calcifications [73].
Antimetabolites:
Methotrexate, 5-fluorouracil, aminopterin, cytarabine, 
mercaptopurine.
Spontaneous abortions [68, 74]. Ventriculomegaly, microcephaly, 
syndactyly, deficient growth and development [75–77].
Cisplatin and carboplatin Sensorineural hearing loss, respiratory distress syndrome [10, 78].
Trastuzumab Kidney injury [79] kidney perfusion [80]. Respiratory failure, 
capillary fragility, and neonatal death [33].
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cer, as well as in the treatment and prognosis, is still un-
der discussion [34]. There are no reports suggesting that 
pregnancy worsens the prognosis. The survival rates of 
pregnant and non-pregnant women with invasive cervical 
cancer are similar [35]. Treatment during pregnancy can 
be selected based on the following circumstances: inten-
tion to maintain the pregnancy, gestational age, and can-
cer stage. During pregnancy, surgical interventions in the 
pelvic area are seriously complicated. Therefore, it is very 
difficult to perform a resection with optimal scope from an 
oncological perspective [36].
In the case of cervical cancer diagnosed after the 20th 
week of pregnancy, the treatment can be postponed until 
foetal maturity. The delivery may be by Caesarean section. 
There are no controlled, randomised studies of the impact 
of this delay on the results of cancer treatment. Howev-
er, possible threats related with cancer treatment should 
be discussed with the patient. If a woman diagnosed with 
cervical cancer in the first trimester of pregnancy wishes 
to maintain the pregnancy, conservative treatment until 
the second trimester is recommended.
Conisation is a treatment of choice at stage IA [37]. 
Conisation and radical trachelectomy are performed if the 
woman intends to maintain the pregnancy. During preg-
nancy, the risk of bleeding increases. To reduce the risk of 
blood loss and abortion, the most favourable time for cer-
vical conisation is in the second trimester, between weeks 
14 and 20 [37]. Radical trachelectomy during pregnancy 
poses great risk and may result in massive bleeding and 
pregnancy loss [38].
Radiation therapy (RT) should not be considered during 
pregnancy if the mother intends to maintain it [39]. In the 
first trimester of pregnancy, RT results in abortion. In the 
second trimester of pregnancy, foetal death occurs after 
10–15 fractions of RT [14].
In pregnant women with cervical cancer at stage IA2–
IB1, lymph node biopsy should be performed first. In the 
case of a negative verification of nodal metastases, treat-
ment can start with neoadjuvant chemotherapy followed 
by trachelectomy. Neoadjuvant chemotherapy may be 
used after the completion of organogenesis (pregnancy 
week 13) [40, 41]. At stage IB2–IIB, neoadjuvant chemo-
therapy is offered once foetal maturity is achieved.
Standard treatment (radical hysterectomy or radioche-
motherapy) is used when lymph nodes are positive. Stan-
dard treatment is considered if there is poor response to 
induction chemotherapy. At more advanced stages (IIA2–
IIIB), classical therapy (radical hysterectomy or radioche-
motherapy) should be used when appropriate gestational 
age is reached.
In conclusion, spontaneous abortion occurred in all pa-
tients treated with radiation therapy. However, in patients 
treated with cisplatin alone administered once a week, 
the course of pregnancy was normal [39]. In the case of 
cervical cancer diagnosed in the first trimester of preg-
nancy, the treatment should be postponed to the second 
trimester. Treatment used in patients with cervical cancer 
diagnosed in the second trimester of pregnancy depends 
on tumour stage. Cervical cancer diagnosed in the third tri-
mester is an indication for Caesarean section due to foetal 
maturity, followed by standard therapy [42].
Lymphomas
Hodgkin’s lymphoma is the most common haemato-
logical malignancy reported during pregnancy. The inci-
dence is estimated at 0.01 per 1,000 pregnancies. Current-
ly, the standard treatment is chemotherapy alone (CTH) or 
in combination with radiation therapy (RT-CTH) [43]. Either 
the area of the irradiated field or the dose of radiation 
(20–30 Gy) is smaller. Treatment using CTH in the second 
and third trimester of pregnancy is considered relative-
ly safe. However, in the case of patients who underwent 
CTH in the first trimester, an increased incidence (6/17) 
of developmental birth defects has been noted. There-
fore, in women diagnosed with Hodgkin’s disease during 
pregnancy, the regimen ABVD (doxorubicin, bleomycin, 
vinblastine, dacarbazine) may be considered at standard 
doses starting from the 2nd trimester [44].
In most cases in which radiation therapy is desired, it 
may be delayed until the birth of the child. In situations 
when radiation therapy is necessary during pregnan-
cy, several case reports have been published that have 
demonstrated the ability to deliver therapeutic doses of 
radiation with very low doses to the developing foetus 
[16]. When modern techniques of radiation therapy are 
used, a reduction in both the irradiated volume and the 
dose absorbed by the foetus may be achieved.
A few-week delay in the consolidation radiation thera-
py may not affect overall survival, and, as in the case of all 
previously discussed decisions, the conversation between 
the patient and the oncologist is important in making ther-
apeutic decisions.
Melanoma
The incidence of melanoma in pregnant women is es-
timated at 0.14–2.8 per 1,000. Melanoma accounts for ap-
proximately 8% of all cancers coexisting with pregnancy 
[45]. The effect of pregnancy on melanoma is not clearly 
established. In patients with melanoma occurring during 
pregnancy, the postpartum placenta must be evaluated in 
order to detect pathological lesions or exclude metasta-
ses. The confirmation of the presence of metastases re-
quires close observation of children for the development 
of cancer [46]. Primary treatment is based on a surgery 
involving excision with a margin of 2.5–5 cm (depending 
on the depth of lesion). At stages I and II, excision of the 
sentinel lymph node can be considered. At stages III and 
IV, lymph nodes along with the possible satellite nodules 
should be cut. Immunotherapy with interferon in pregnant 
women with metastatic melanoma appears to be safe [46, 
47]. Adjuvant radiation therapy in pregnancy is limited to 
the lesions of the head and neck, brain metastases, and 
palliative treatment of recurrent or metastatic disease at 
sites other than the central nervous system. Metastases 
in the brain (if limited) are often treated with radiosurgery 
or neurosurgical resection. Delaying the treatment of met-
astatic lesions in the brain is not advisable. Radiosurgery 
delivers very high doses to very small volumes in the brain 
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and, with careful treatment planning, it should be possible 
to treat a pregnant patient with a minimal exposure to the 
foetus [48]. Chemotherapy is of no practical use in such 
cases [49].
Thyroid cancer
Thyroid cancer has a reported incidence of 14 cases 
per 100,000 pregnant women [50]. For all patients with 
tumour nodules or nodules that grow quickly, a surgery 
should be offered in the second trimester of pregnancy. 
Patients with early-stage follicular and papillary thyroid 
cancer are candidates for delaying the surgery because 
the lesions generally grow slowly [51]. No cases of accel-
erated locoregional recurrence or decreased survival have 
been reported in pregnant patients with thyroid cancer, as 
compared with non-pregnant patients [52].
Ovarian cancer
Ovarian cancer in pregnancy is rare and has occurred 
in 1 in 15,000 to 1 in 32,000 pregnancies. During pregnan-
cy, malignant and borderline ovarian cancers account for 
3% to 6% of cases. Ovarian pathologic types include epi-
thelial (49–75%), germ-cell (6–40%), and sex cord stromal 
tumours (9–16%) [53]. Because tumour markers during 
pregnancy are not helpful, the diagnostic methods mainly 
depend on ultrasonographic findings. Surgical interven-
tions conducted too early may increase the risk of loss of 
luteal function and abortion. Therefore, it is recommended 
to conduct such interventions in the second trimester [53].
As germ cell tumours are sensitive to chemotherapy, fer-
tility-sparing surgery (cytoreduction) is also recommended 
at advanced stages of the disease, even if the other ovary 
is intact. However, in the case of ovarian cancer, cytoreduc-
tive surgery should only be considered at stage IA/IB [53]. 
Advanced stages of ovarian cancer can be treated using 
various methods, including basic cytoreductive surgery fol-
lowed by parturition, surgery during pregnancy followed 
by adjuvant chemotherapy after parturition, reductive 
surgery followed by chemotherapy during pregnancy and 
after parturition, and surgery during pregnancy followed 
by suspension of treatment [54–56].
Maintaining the pregnancy is very difficult if cancer 
has been diagnosed before the 20th week. After 20 weeks 
of pregnancy, maintaining the pregnancy is possible but 
uncertain. Similarly as in non-pregnant women, the treat-
ment of choice for preoperative chemotherapy is carbopla-
tin + paclitaxel until foetal maturity [57, 58].
Colorectal cancer
Colorectal cancer in pregnancy is rare, and has oc-
curred in 1 in 13,000 pregnancies [59]. The treatment and 
the prognosis in pregnant patients with colorectal cancer 
do not differ from those in the general population. There 
are several factors to be considered when planning the 
treatment: tumour location, gestational age, stage of 
the tumour, complications due to the tumour or due to 
the pregnancy, and the patient’s decision. Unfortunately, 
colorectal cancer is often diagnosed during pregnancy at 
an advanced stage, when surgical treatment and comple-
mentary chemotherapy demonstrate poor efficacy [60]. 
Surgery may be conducted safely before the 20th week of 
pregnancy [61]. It has been proposed that colorectal cancer 
surgery be conducted immediately after uncomplicated 
Caesarean section [60, 62].
Chemotherapy employing 5-fluorouracil (5-FU) used as 
standard treatment at stage III of colorectal cancer caus-
es a high risk of teratogenic effect [60]. The most serious 
complications in chemotherapy occur between week 3 and 
week 12 of foetal life. In several case reports, chemothera-
py using 5-FU in the first trimester of pregnancy resulted 
in spontaneous abortion [63, 64].
Cisplatin and its derivative chemotherapeutics are 
also used in the treatment of colorectal cancer, but they 
are not recommended during breastfeeding or pregnancy. 
Chemotherapy is safer in the second and third trimester of 
pregnancy, although an increase in the occurrence of in-
trauterine growth retardation and premature delivery has 
been observed [26].
Supportive treatment
Antiemetics (ondansetron, metoclopramide) may be 
safely used with cover corticosteroids during the first tri-
mester of pregnancy [65]. The use of tropisetron is discour-
aged: studies have shown teratogenic effects in animals. 
Granisetron and palonosetron are rarely used in pregnan-
cy. Analgesics (paracetamol, opioids, anti-inflammatory 
agents) were administered to pregnant women and, with 
the exception of the first trimester, did not generate ad-
verse effects, but there is some risk of respiratory depres-
sion and foetal ductus arteriosus closure [66]. Bisphos-
phonates and somatostatin should be postponed until 
after the delivery due to their teratogenic effect observed 
in animals and humans. Treatment with anti-infective 
agents should follow the guidelines to avoid the terato-
genic effects of these drugs.
The decision on the introduction and continuation of 
treatment in the event of pregnancy should be preceded 
by a detailed analysis of the potential benefits and risks. 
There are no data to suggest that pregnancy termination 
alters the biological behaviour of the tumour or patient 
prognosis in the presence of appropriate antineoplastic 
therapy. All patients should be given appropriate advice 
and informed that there are insufficient scientific data to 
determine any generally accepted consensus. It is very im-
portant to always respect the will of the patient, and the 
moral judgment of a physician should have no impact on 
the decisions taken by the woman. If the woman decides 
to undergo active treatment and maintain her pregnancy, 
it is necessary to carry out consultations with experts in 
the field appropriate to the type of cancer.
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